Substances from urinary extracts of normal, nonpregnant subjects and human pituitary gonadotropin preparations were found to react similarly to human chorionic gonadotropin (hCG) in a radioimmunoassay system that is highly specific for hCG and without crossreactivity to human luteinizing hormone (hLH). The COOH-terminus of the hCG,# subunit (6, 7). Unexpectedly, in radioimmunoassays using this antiserum and 125I-hCG, both the urinary extracts previously thought not to contain hCG and pituitary extracts were found to give rise to dose-response curves indistinguishable from those of highly purified hCG. These results were similar to those of the earlier assays (2). In order to elucidate the basis for these unexpected observations, radioimmunoassays were carried out prior to and following gel filtration of these extracts on Sephadex G-100. The results indicate that substances with immunological, physical, and biological properties of hCG are present in both crude and partially purified urinarygonadotropin preparations 
rabbit immunized with a bovine albumin conjugate of the unique carboxyl-terminal peptide (residues 123-145) isolated from a tryptic digest of the reduced, S-carboxymethylated hCG,8 subunit. The antibody recognition site on the peptide was found to reside on the last 15 amino acid residues of the carboxyl-terminal peptide, as evidenced by the competitive binding activities against 25I-labeled hCG of a series of peptides chemically synthesized according to the carboxyl-terminal sequence of HCG#. In order to elucidate the nature of the crossreacting substance in urinary extracts, a human postmenopausal urinary preparation (Pergonal) and a kaolin-acetone extract of urine from a patient with Klinefelteris syndrome were subjected to gel chromatography on Sephadex G-100. The results indicate that fractions showing immunocrossreactivity with the antiserum to hCGft-carboxyl-terminal peptide coeluted with 125I-labeled hCG which was separated distinctly from hLH. The same fractions from this postmenopausal urinary gonadotropin preparation exhibited in vitro biological activity proportional to the immunocrossreactivity of the hCG-specific antiserum.
Concentration of postmenopausal women's urine by acetone precipitation retained approximately five times more immunoreactivity per unit volume than kaolin-acetone extraction, when assayed with the antiserum to hCGO-carboxyl-terminal peptide. The development of practical, sensitive, and specific assays for distinguishing human chorionic gonadotropin (hCG, choriogonadotropin) from human luteinizing hormone (hLH, lutropin) in serum and urine specimens, collected for diagnostic purposes from pregnant women and persons with neoplasms secreting hCG, has been a major objective of the Reproduction Research Branch, National Institute of Child Health and Human Development, and its collaborators. Radioimmunoassays, specific for hCG in serum, have been developed and one of these has been applied extensively in clinical practice (1) and in clinical investigation (2) (3) (4) . With these assays it was observed that extracts of urine from persons who were not pregnant or did not have a neoplasm as well as extracts of human pituitary tissue, thought not to contain hCG, showed significant crossreactivity with 125I-hCG. These data led to the assumption that, while this assay appeared to be specific for hCG in serum, it Abbreviations: h, human; CG, chorionic gonadotropin (choriogonadotropin); LH, luteinizing hormone (lutropin); FSH, follicle-stimulating hormone (follitropin); 2IRPHMG, second international reference preparation of human postmenopausal gonadotropin.
could not be used to distinguish hCG from hLH in pituitary and urinary extracts.
Efforts to develop assays to make this distinction have continued by producing antisera, in rabbits, directed at antigenic sites that are known to be present in hCG but not in hL (5 (6, 7) . Unexpectedly, in radioimmunoassays using this antiserum and 125I-hCG, both the urinary extracts previously thought not to contain hCG and pituitary extracts were found to give rise to dose-response curves indistinguishable from those of highly purified hCG. These results were similar to those of the earlier assays (2) . In order to elucidate the basis for these unexpected observations, radioimmunoassays were carried out prior to and following gel filtration of these extracts on Sephadex G-100. The Donini et al. (10) , and Canfield et al. (11) were tested in radioimmunoassays: (1) second international reference preparation of human postmenopausal gonadotropin (2IRPHMG) with biological activity of 40 international units (IU) per ampoule or 1 IU = 0.2295 mg for both hLH and human follicle-stimulating hormone (hFSH, follitropin); (2) (14) . Cleavage from resin and removal of protecting groups were accomplished by treatment with liquid hydrogen fluoride.
Peptides other than the four peptides mentioned above were synthesized also by the solid phase method, except S-methylcysteinyldehydroalanine was coupled to the resin prior to the elongation of peptide. Peptides were cleaved from the resin by 1 M HCl in glacial acetic acid. O-Benzyl groups were removed by HBr gas in trifluoroacetic acid containing anisole. Thus, the peptides produced from this series contain COOH-terminal S-methylcysteinyl amide. Arginine is in the form of N-nitroguanidinoarginine. S-Methylcysteinyl amide residue was not included in the counting of chain length as shown in Fig. 1 shown in Fig. 2 , where it can be seen that slopes 4 sponse curves for these materials were indistingui masses required for equivalent inhibition of bin virtually the same. On the basis of these data, it so sonable to consider that this assay would be speci peptide in which these antigenic determinants si anti-hCGf#-COOH-terminal serum, but also with the Sb6 anti-hCGj3 serum (which distinguishes hCG from hLH in serum), the H80 anti-hCG serum(which distinguishes hCG and of dose-rehLH from hFSH and human thyrotropin in serum and pituitary ishable and and urinary extracts, but does not distinguish hCG from hLH iding were in a mixture of these two hormones) and the H31 anti-ovine eemed rea-FSH serum (18) (which is specific for hFSH in serum and in fic for any urinary and pituitary extracts). Results are shown in Fig.  hared with 3A-E. 3 . Sephadex G-100 gel chromatographic patterns of human postmenopausal gonadotropin preparation (Pergonal) as determined by radioimmunoassay systems from a single column run using antisera of different specificities. Two ml containing 300 LU (bioassay, 2IRPHMG) were applied to the column. A/S is antiserum, with dilution given in parentheses. VO is void volume; Vt is total column volume.
In Fig. 3A , the elution volume of 125I-hCG is shown. A symmetrical peak of radioactivity was seen, beginning with tube 70, reaching a fastigium (peak) at tube 78, and declining to baseline at tube 87. For this column the partition coefficient K5v is 0.24 and the Ve/Vo ratio (elution volume/void volume) is 1.56 for 125I-hCG.
Fractions collected when the Pergonal preparation was applied to this column were assayed with the H93 antiserum to hCGf-COOH-terminal peptide, and the results are shown in Fig. SB . A symmetrical peak of immunoreactivity was found to be coincident with that for the 125I-hCG radioactivity in Fig.  SA . When the same fractions were assayed with the Sb6 antihCG,3 serum, a coincident immunoreactivity peak was seen (Fig. 3C ), but this peak was asymmetrical, with a shoulder on the descending limb, extending from tubes 83 to 90. As can be seen in the data presented below with the H80 assay, we believe this shoulder represents some crossreactivity of Sb6 antiserum with hLH.
When these fractions were assayed with the H80 anti-hCG serum, two overlapping peaks of immunoreactivity were seen (Fig. SD) . The first and smaller of these was coincident with those seen in the other two assays, whereas the second and larger peak was coincident with the shoulder seen by the Sb6 assay (Fig. 3C ). This second peak reached its fastigium in tube 87 and was coincident with the peak of hFSH immunoreactivity found when these fractions were tested with the HS1 radioimmunoassay for hFSH (Fig. 3E) .
Collectively, these data were interpreted to indicate that the substances in the postmenopausal urine extract that shared antigenic determinants with the COOH-terminal region of hCGfl also exhibited the physical characteristics of hCG as manifested by elution pattern in Sephadex G-100 column chromatography.
Despite the fact that immunoreactivity similar to that for hCG was demonstrated in four separate postmenopausal urine extracts, the remote possibility of inadvertent contamination of all four preparations with pregnancy urine or urine from persons with neoplasms cannot be eliminated. Accordingly, a 24 hr urine specimen was collected from a young man with Klinefelter's syndrome and was processed by the method of Albert (9) . An aliquot of this kaolin-acetone extract containing biopotency of 500 mouse uterus units and 36.75 IU LH (immunoassay, H80 antiserum, 2IRPHMG) was applied to the Sephadex G-100 column. Fractions were collected and assayed in the same manner as had been done for Pergonal. Results are shown in Fig. 4A-D . Despite the fact that this urine extract is crude as compared to Pergonal, an immunoreactive peak coincident with that for 125I-hCG was seen in all three assays (Fig. 4B-D) . In addition, the shoulder and overlapping second peak recognized by Sb6 anti-hCG(3 serum assays of Pergonal fractions were seen in the corresponding fractions of this crude urine extract.
Although the Ve/Vo ratio of this substance in postmenopausal urine extracts is more consistent with that reported for hCG than for hCGj3 (13) , hCG,3 is antigenically potent in all the assays used in these studies. To (20) . This conclusion was reached on the basis of the "biologic fingerprint" of 2IRPHMG. It was not possible to distinguish incidental contamination with pregnancy urine from an endogenous source of an hCG-like gonadotropin in postmenopausal women.
Although we cannot eliminate the possibility of inadvertent contamination of pooled specimens by pregnancy urine or urine from persons bearing neoplasms, the possibility of such contamination seems extremely remote in the case of the acetone precipitates we obtained from postmenopausal nuns' urine and a urine extract from a patient with Klinefelter's syndrome. Acetone precipitation was found to be a more effective means of concentrating the immunoreactive substance than the kaolin-acetone extraction. Kaolin-acetone extracts of specimens containing up to 50 mouse uterus units of total urinary gonadotropin did not contain measurable immunoreactivity in the H93 assay (21) .
Since urinary preparations contained substances that shared antigenic determinants with those of the COOH-terminal peptide of hCG3, the autogenous source seems more plausible.
In addition, the observation that similar antigenic activity was present in pituitary extracts suggests that the pituitary may be a source of this substance. To our knowledge, neither the observation that pituitary extracts contain a substance with such antigenic properties nor the possibility that the pituitary may be a source of similar substances in human urinary extracts has been reported hitherto. However, it has been reported that extracts of human testis contain a substance with physical and antigenic properties of hCG (22) . These observations raise questions as to whether the mere presence of hCG as a "marker" (23) can be useful for diagnosing or monitoring treatment of some human neoplasms. Thus, the validity of hCG as a "marker" must depend on considerations such as its origin, levels, and patterns of secretion. Equally important implications for the design of highly sensitive qualitative tests for hCG in serum and urine for pregnancy tests are obvious. Moreoever, irrespective of the source of these substances that can be detected antigenically in pituitary and urinary extracts, these observations have implication for human reproductive physiology and pathophysiology, and ultimately for clinical practice and investigation.
